A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
INVENTIVA operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -199M | -199M | -120M | -57M | -59M | -39M |
| EPS | $-3.33 | $-3.33 | $-2.64 | $-1.38 | $-1.50 | $-1.14 |
| Free Cash Flow | -93M | -93M | -89M | -47M | -56M | -35M |
| ROIC | -64.8% | -64.8% | -116.6% | -38.9% | -327.3% | -168.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | - | 0.88 | 0.12 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -105M | -105M | -112M | -60M | -61M | -34M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | - | -1829.6% | -74.8% | -50.4% | -44.4% |
| Shares Outstanding | 60M | 60M | 45M | 41M | 39M | 34M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | -38M | -27M | -57M | -64M | -119M | -98M | -98M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -34M | -34M | -61M | -60M | -112M | -105M | -105M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -34M | -39M | -59M | -57M | -120M | -199M | -199M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/M | -168.9% | N/M | -38.9% | -116.6% | -64.8% | -64.8% |
| ROE | -73.0% | -44.4% | -50.4% | -74.8% | -1829.6% | N/A | 0.0% |
| ROA | -53.1% | -34.6% | -38.6% | -43.0% | -121.3% | -195.1% | -154.8% |
| Cash Flow | |||||||
| Op. Cash Flow | -32M | -35M | -56M | -47M | -89M | -93M | -93M |
| Free Cash Flow | -32M | -35M | -56M | -47M | -89M | -93M | -93M |
| Owner Earnings | -33M | -36M | -59M | -50M | -93M | -97M | -97M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 56K | 882K | 315K | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.6M | 1.1M | 2.5M | 2.3M | 4.3M | 3.9M | 3.9M |
| Debt Repayment | 163K | 70K | 15K | 1.1M | 2.7M | 2.8M | 2.8M |
| Balance Sheet | |||||||
| Net Debt | -38M | -106M | -90M | -49M | 27M | 9.0M | -104M |
| Cash & Equiv. | 40M | 121M | 102M | 91M | 29M | 104M | 104M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.04 | 0.12 | 0.12 | 0.88 | N/A | N/A | 0.00 |
| Interest Coverage | -374.2 | -5.0 | -19.8 | -27.1 | -14.9 | -1.1 | -1.1 |
| Equity | 46M | 128M | 105M | 48M | -35M | -115M | -115M |
| Total Assets | 64M | 160M | 144M | 122M | 76M | 129M | 129M |
| Total Liabilities | 17M | 32M | 39M | 74M | N/A | N/A | N/A |
| Intangibles | N/A | N/A | N/A | 598K | 587K | 52K | 52K |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 39M | 137M | 109M | 80M | -2.1M | -10.0M | -10.0M |
| Current Assets | 55M | 153M | 136M | 112M | 52M | 120M | 120M |
| Current Liabilities | 16M | 16M | 27M | 32M | 54M | 130M | 130M |
| Per Share Data | |||||||
| EPS | N/A | -1.14 | -1.50 | -1.38 | -2.64 | -3.33 | -3.33 |
| Owner EPS | N/A | -1.07 | -1.50 | -1.20 | -2.04 | -1.62 | -1.62 |
| Book Value | N/A | 3.76 | 2.68 | 1.16 | -0.77 | -1.93 | -1.93 |
| Cash Flow/Share | N/A | -1.03 | -1.44 | -1.14 | -1.95 | -1.55 | -3.33 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 34.0M | 39.1M | 41.4M | 45.4M | 59.8M | 59.8M |
| Valuation | |||||||
| P/E Ratio | N/A | -11.1 | -9.2 | -3.1 | -1.7 | -0.7 | -1.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.3 | 5.1 | 3.8 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -8.2% | -10.4% | -26.3% | -43.1% | -68.4% | -35.2% |
| Market Cap | 0 | 428M | 538M | 180M | 206M | 136M | 264M |
| Avg. Price | 3.52 | 8.68 | 13.97 | 7.90 | 4.15 | 2.97 | 4.41 |
| Year-End Price | 3.86 | 12.60 | 13.77 | 4.34 | 4.53 | 2.27 | 4.41 |
INVENTIVA passes 0 of 9 quality checks, indicating weak fundamentals.
INVENTIVA (IVA-PA) has a 5-year average return on invested capital (ROIC) of -97.3%. This is below average and may indicate limited pricing power.
INVENTIVA (IVA-PA) has a market capitalization of $264M. It is classified as a small-cap stock.
INVENTIVA (IVA-PA) does not currently pay a regular dividend.
INVENTIVA (IVA-PA) operates in the Biotechnology industry, within the Healthcare sector.
INVENTIVA (IVA-PA) generated $-93 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
INVENTIVA (IVA-PA) reported earnings per share (EPS) of $-3.33 in its most recent fiscal year.
The Ledger Terminal provides 6 years of financial data for INVENTIVA (IVA-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INVENTIVA (IVA-PA) has a book value per share of $-1.93, based on its most recent annual SEC filing.